Benralizumab as a potential treatment of asthma

References

• Antoniu SA. Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs. 2009;23(4):241–251.
   PubMed Web of Science ®Google Scholar
• Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1–2):17–27.
   PubMedGoogle Scholar
• Takaki S, Kanazawa H, Shiiba M, et al. A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction. Mol Cell Biol. 1994;14(11):7404–7413.
   PubMed Web of Science ®Google Scholar
• Reed JL, Kolbeck MN, Kozich AA, et al. MEDI-563 a humanized anti-IL-5Ra antibody with enhanced effector function induces reversible blood eosinopenia in mild asthmatics. J Allergy Clin Immunol. 2010;121(2):S47.
   Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353e1342.
   PubMed Web of Science ®Google Scholar
• Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113–118.
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125(6):1237–1244e1232.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. A study to evaluate the safety, tolerability and effects of MEDI-563 in adults with asthma. ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 2016 Nov 23]. Available from: https://clinicaltrials.gov/show/NCT00659659. NLM Identifier: NCT00659659.
   Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096e1085.
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. A phase 2 study to evaluate the safety and efficacy of intravenously administered MEDI-563 (MEDI-563). ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 2016 Nov 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT00768079?term=benralizumab&rank=11. NLM Identifier: NCT00768079.
   Google Scholar
• AstraZeneca. Efficacy and safety study of benralizumab in adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting β2 agonist. ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 2016 Nov 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01914757?term=benralizumab&rank=2. NLM Identifier: NCT01914757.
   Google Scholar
• AstraZeneca. Study to assess functionality, reliability, and performance of a single-use auto-injector with benralizumab administered at home (GRECO). ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US). 2000 [cited 2016 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02918071?term=benralizumab&rank=1. NLM identifier NCT0291807.
   Google Scholar
• AstraZeneca. A safety extension study to evaluate the safety and tolerability of benralizumab (MEDI-563) in asthmatic adults and adolescents on inhaled corticosteroid plus LABA (BORA). ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 23 Nov 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT02258542?term=benralizumab&rank=3. NLM Identifier: NCT02258542.
   Google Scholar
• AstraZeneca. A study to evaluate the onset of effect and time course of change in lung function with benralizumab in severe, uncontrolled asthma patients with eosinophilic inflammation (SOLANA). ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 2016 Nov 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02869438?term=benralizumab&rank=5. NLM Identifier NCT02869438.
   Google Scholar
• AstraZeneca. A safety extension study with benralizumab for asthmatic adults on inhaled corticosteroid plus long-acting β2 agonist. ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 2016 Nov 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02808819?term=benralizumab&rank=8. NLM Identifier NCT02808819.
   Google Scholar
• AstraZeneca. Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma. ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine (US).2000 [cited 2016 Nov 23]. Available from: https://clinicaltrials.gov/show/NCT01928771. NLM Identifier: NCT01928771.
   Google Scholar
• Newbold P, Wu Y, Shih V, et al. Efficacy and safety study of benralizumab in adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting β2 agonist. Am J Respiratory Crit Care Med. 2016;193(1):A4351.
   Google Scholar
• Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29.
   PubMed Web of Science ®Google Scholar